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Background. Up to 60% of patients with a positive sentinel lymph node (SLN) have no additional nodal involvement and do not
beneﬁt from completion axillary lymph node dissection (ALND). We aim to identify factors predicting for non-SLN involvement
and to validate the MSKCC nomogram and Tenon score in our population. Methods. Retrospective review was performed of 110
consecutive patients with positive SLNs who underwent ALND over an 8-year period. Results. Fifty patients (45%) had non-
SLN involvement. Non-SLN involvement correlated positively with the number of positive SLNs (P = 0.04), macrometastasis
(P = 0.01), and inversely with the total number of SLNs harvested (P = 0.03). The MSKCC nomogram and Tenon score both
failed to perform as previously reported. Conclusions. The MSKCC nomogram and Tenon score have limited value in our practice.
Instead, we identiﬁed three independent predictors, which are more relevant in guiding the intraoperative decision for ALND.
1.Introduction
Sentinel lymph node (SLN) biopsy is the current standard
of care for T1 T2 breast cancers with no clinically palpable
axillary lymph nodes. Based on the principle of sequential
directional lymphatic drainage from the breast, the SLN is
hypothetically the ﬁrst axillary node to receive lymphatic
drainage from the breast. It, therefore, follows that if the
SLN is free of metastatic tumour deposits, the rest of the ax-
illarynodes arenotexpectedtobeinvolved either.Thisoblit-
erates the need for full axillary lymph node dissection
(ALND) when the SLN is negative for metastases. ALND, in-
volving the removal of the level I and II axillary nodes, is
now reserved for instances where the SLN is positive for
metastases or where SLN biopsy is contraindicated. This has
resulted in more than 50% of patients with T1 and T2 tum-
oursbeingsparedthearmmorbidityofALNDbecauseofthe
less extensive dissection [1, 2].
However, it is known that up to 60% of patients with
a positive SLN do not have additional nodal involvement,
suggesting that these patients are overtreated by the current
practice of ALND whenever the SLN is positive [3, 4]. The
removal of uninvolved nodes serves neither to aid prognosti-
cation nor to guide adjuvant therapy, yet exposes the patient
to the risk of lymphedema and its associated complications.
This has led to some questioning the need for ALND in all
instancesofSLNpositivity[5].TheAmericanCollegeofSur-
geons Oncology Group Z0011 trial is the latest to show that
women with T1 and T2 tumours who undergo lumpectomy
derive little additional beneﬁt from ALND since any residual
disease in the level I and II nodes appear to be eﬀectively
eradicated by postoperative irradiation and chemotherapy
[6, 7]. It remains to be seen whether the evidence so far will
changecurrentguidelines.Mostcentrescontinuetoadvocate
ALND when the SLN is positive. Given the reluctance of
most surgeons to leave behind residual disease in the axilla,2 ISRN Oncology
a reliable means of predicting the likelihood of non-SLN in-
volvement will be a step towards reﬁning the indication for
ALND. To date, there are 4 nomograms (Memorial Sloan-
Kettering Cancer Centre [MSKCC] nomogram [8], Mayo
nomogram[9],Cambridgenomogram[10]andtheStanford
nomogram [11]), 3 scoring systems (the Tenon score [12],
the MD Anderson Cancer Centre score [13] and the score
developed by Saidi et al. [14]) and 2 recursive partitioning
tools developed by Kohrt et al. [11]. In a direct comparison
of these models, the MSKCC nomogram and the Tenon
score performed best and were the only 2 models with an
area under the curve (AUC) of more than 0.75 [15].
In our practice, the decision for ALND is made intraop-
eratively based on frozen section analysis of the SLN. Apart
from guiding the decision to proceed with ALND during
surgery, a reliable means of predicting the status of the non-
SLN nodes will also reduce patient recall rates should the
initial frozen section analysis be false negative. We, therefore,
aim to determine the incidence of non-SLN involvement in
our patients, and to identify factors that may predict for this.
In addition, we aim to validate the MSKCC nomogram and
the Tenon score in our local population.
2. Methods
Ar e t r o s p e c t i v er e v i e ww a sp e r formed of 110 consecutive pa-
tients with a positive SLN who underwent ALND from 1st
January2001to31stDecember2008inourdepartment.This
study has ethics committee approval (DSRB D/10/029). In
our department, the majority of SLN biopsy is performed
with blue dye alone. Two mL of undiluted patent V blue dye
is injected into the subareolar plexus after the patient is put
under general anaesthesia, followed by 5 minutes of manual
massage. The SLN is identiﬁed as a blue-coloured node with
a blue lymphatic channel leading up to it. Beginning from
the year 2006, all SLNs were routinely submitted for intra-
operative frozen section analysis (a total of 64 patients).
This involves the documentation of the number and size of
SLNs submitted for analysis, followed by histological exam-
inationofserialsectionsstainedwithhaematoxylinandeosin
(H&E). Each SLN is serially sliced at 2 to 3mm gross in-
tervals, and all slices (the entire node) are snap frozen in liq-
uid nitrogen and then placed in frozen section embedding
medium on a cryostat object disk. Each slice is then further
sectioned at intervals of 40µm to obtain at least 3 sections,
which are stained in H&E and examined using routine light
microscopy. The presence or absence of metastatic deposits
is noted and communicated to the surgeon immediately. If
the SLN is positive for macro- or micrometastasis, ALND is
immediately proceeded with; if negative, no further axillary
dissection is performed. The entire SLN is then formalin
ﬁxed and paraﬃn embedded to obtain permanent sections
for ﬁnal analysis, where an additional 1 to 6 levels of each
sliceoftheSLNareexamined.Itisnotroutineinourpractice
to perform immunohistochemistry or quantitative real-time
polymerase chain reactions on H&E-negative sections. For
the 46 patients who underwent surgery prior to 2006, only
serialH&EanalysisofthepermanentsectionsoftheSLNwas
performed (without frozen section analysis).
The presence of metastatic deposits in the SLN and non-
SLNs was correlated with standard clinicopathological pa-
rameters including histology of the primary tumour, tumour
size, tumour grade, presence of lymphovascular invasion,
and hormone and human epidermal growth factor receptor
2 (HER2) receptor status. Note was also made of whether
the metastatic deposit was classiﬁed as a macrometastasis or
micrometastasis. Macrometastases are deﬁned as cell clusters
that are more than 2mm in diameter; micrometastatic de-
posits are deﬁned as cell clusters that are between 0.2mm
and2mmindiameter(denotedasN1mic accordingtothe6th
AJCC classiﬁcation). Correlation analyses were performed
using either the chi square test or Fisher’s exact test where
appropriate. Correlation with tumour grade was evaluated
using the Chi square test for trend. All univariate analyses
were performed with GraphPadPrism version 4 (GraphPad
software Inc., San Diego CA). The Cox proportional hazard
regression model was used to identify independent risk
factors for non-SLN involvement. This was carried out
using the Stata package release 8.1 (Stata Corporation, 4905
Lakeway Drive, College Station, Texas 77845, USA). A full
model was ﬁrst created to include all potentially important
explanatory variables. At each step, the variable with the
smallest contribution to the model was removed, until a ﬁnal
backward stepwise model was obtained. A 2-tailed P value
test was used in all analyses and a P value of less than 0.05
was considered statistically signiﬁcant.
The probability of non-SLN involvement was calculat-
ed based on the MSKCC nomogram and Tenon score.
The MSKCC nomogram is based on tumour histology and
grade, pathological tumour size, multifocality, lymphovas-
cular invasion, oestrogen receptor (ER) status, the number
of positive and negative SLNs, and the mode of detection (in
our study, SLN biopsy cases prior to 2006 were performed
with serial H&E examination of the permanent sections, and
those from 2006 onwards were assessed with intra.opera-
tive frozen section analysis). The combined score of each
variable is translated into a predicted probability of non-
SLN involvement. The nomogram is available as an elec-
tronic calculator on the MSKCC website (http://www.mskcc.
org/mskcc/html/15938.cfm). The Tenon score is calculated
based on three variables: the ratio of positive SLN to the total
number of SLN removed, the presence of micrometastasis
in the SLN, and the primary tumour size, combined to give
as c o r ef r o m0t o7[ 12]. Receiver operating characteristic
(ROC) curves based on both models were generated and the
area under ROC curve (AUC) calculated using Stata package
release 8.1. AUC ranged from 0 to 1, where 1 indicates per-
fect concordance, 0.5 indicates no better concordance than
chance, and 0 indicates perfect disconcordance.
3. Results
From 1st January 2001 to 31st December 2008, a total of
551 patients underwent SLNB in our centre; of these, 110
patients underwent completion ALND after a positive SLN
was found. Median patient age was 53 years (30 to 80 years).
All patients were diagnosed with invasive carcinoma; 88%
(97 of 110) were classiﬁed as invasive ductal carcinoma, 10%ISRN Oncology 3
Table 1: Correlation analyses of SLN involvement and clinicopathological parameters (n = 110).
Patients with SLN positive only
(n = 60)
Patients with non-SLN involvement
(n = 50) P value
Median age (years) 54.0 (37.0 to 80.0) 51.5 (30.0 to 77.0) 0.42
Ethnicity 0.70
Chinese 47 36
Malay 8 8
Indian 2 4
Others 3 2
Family history of breast cancer 0.53
Yes 7 8
No 52 42
Tumour histology 0.20
IDC 56 42
ILC 4 7
Median tumour size (mm) 20.0 (4.0 to 80.0) 24.5 (1.0 t o 55.0) 0.03
Tumour grade 0.99
15 6
22 8 1 9
32 6 2 3
Lymphovascular invasion 0.81
Present 26 22
Absent 29 27
Associated DCIS 0.97
EIC 10 8
DCIS 25 19
None 22 17
Oestrogen receptor status 0.84
Positive 42 35
Negative 17 13
Progesterone receptor status 0.42
Positive 31 21
Negative 28 26
HER2 status 0.16
Positive 16 10
Negative 27 33
Size of nodal disease 0.01
Macrometastases 46 49
Micrometastases 14 1
Ratio of positive SLN to total SLN
harvested
0.01
<0.5 20 8
0.5 to 1 14 8
12 6 3 4
Number of axillary nodes 0.03
<10 11 3
10 to 20 25 16
20 to 30 17 24
>30 7 74 ISRN Oncology
Table 1: Continued.
Patients with SLN positive only
(n = 60)
Patients with non-SLN involvement
(n = 50) P value
Distant recurrence 0.34
Yes 5 7
No 55 43
Median Tenon score 5.0 (1.5 to 7.0) 5.75 (2 to 7) <0.001
Median MSKCC probability 19.5 (3.0 to 74.0) 41.0 (6.0 to 89.0) <0.001
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Figure 1: Receiver operating characteristics (ROCs) curve assessing
the discriminatory ability of the MSKCC nomogram.
as invasive lobular carcinoma. One patient had a medullary
carcinoma and another a mucinous carcinoma. Median
pathological tumour size was 21mm (4mm to 80mm), and
median tumour grade was 2. Seventy percent of patients
had oestrogen receptor (ER) positive tumours, and 47% had
progesterone receptor (PR) positive tumours. The median
number of SLN harvested was 2 (1 to 9). All except 9
SLN biopsies were performed using blue dye alone, 6 were
performed using dual blue dye and radiocolloid, and 3
were performed with radiocolloid alone. Median number
of axillary lymph nodes harvested (including SLNs) was 22
(ranging from 7 to 58).
The SLN was the only positive axillary node in 60 of
110 patients (55%). The likelihood of non-SLN involvement
correlated positively with pathological tumour size (P =
0.03); median tumour size was 24.5mm in cases of non-SLN
involvement compared to 20mm in those where only the
SLN was involved. Non-SLN involvement was also inversely
correlated with the ratio of positive SLNs to the total number
of SLNs harvested (P = 0.01) (Table 1). Those with a ratio
of 0.5 or more were 3 times more likely to have non-SLN
involvement (P = 0.04, OR 2.63, 95% CI 1.04 to 6.64),
implying that additional non-SLN involvement became less
l i k e l yw h e nm o r eh a r v e s t e dS L N sw e r en e g a t i v e .T h es i z eo f
the metastatic deposits also correlated with the likelihood
of non-SLN involvement, with macrometastasis (rather than
micrometastasis) being associated with involvement of the
non-SLNs (P = 0.01, OR = 14.9, 95% CI 0.01 to 0.53)
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Figure 2: Receiver operating characteristics (ROC) curve assessing
the discriminatory ability of the Tenon score.
(Table 1). Non-SLN involvement did not correlate with
tumour histology, tumour grade, lymphovascular invasion,
or hormone receptor status (P>0.05) (Table 1). Non-
SLN involvement also did not increase the likelihood of
distant recurrence. On multivariate analysis, the number of
positive SLNs, total number of SLNs harvested, presence
of micrometastasis, and the total number of axillary nodes
harvested during ALND independently predicted for non-
SLN involvement (P<0.05) (Table 2). Interestingly, tumour
size did not remain signiﬁcant (P = 0.14) (Table 2).
The MSKCC nomogram and the Tenon score were vali-
dated in our study population. Based on the MSKCC nom-
ogram, the median calculated probability in the group with
SLN involvement alone was 19.5%, signiﬁcantly lower than
the calculated probability of 41.0% in the group with addi-
tional non-SLN involvement (P<0.001) (Table 1). The
discriminatory ability, as calculated from the area under the
receiver operating curve (ROC) (AUC), was 0.69 (Figure 1).
Similarly, the Tenon score also diﬀerentiated the group with
SLN involvement alone from the group with additional non-
SLN involvement (median score of 5.0 and 5.75 resp., P<
0.001), with an AUC of 0.71 (Figure 2).
The subgroup of 15 patients (13.6%) with micrometas-
tasis was further evaluated. Median tumour size was 20mm
(12mm to 40mm), median tumour grade was 2, and
lymphovascular invasion was present in 10 patients (66.7%).
Thirteen tumours were classiﬁed as invasive ductal carci-
noma, 1 as invasive lobular carcinoma, and 1 as mucinousISRN Oncology 5
Table 2: Multivariate analysis Cox regression model for non-SLN involvement for standard clinicopathological parameters (n = 110).
Odds ratio P value 95% conﬁdence interval
Number of positive SLNs 2.05 0.04 1.04–4.01
Total number of SLNs harvested 0.73 0.03 0.55–0.96
Micrometastasis 0.06 0.01 0.01–0.54
Tumour size 1.03 0.14 0.99–1.07
Total number of axillary LN harvested 1.06 0.03 1.01–1.12
carcinoma. Calculated median Tenon score was 3.5 (1.5 to
5.0), and median predicted probability based on the MSKCC
nomogram was 18% (7 to 51%). Only 1 patient (with a
25mm invasive lobular carcinoma) had additional non-SLN
involvement; calculated Tenon score was 5.0, and MSKCC
predicted probability of non-SLN involvement was 18%.
4. Discussion
Involvement of the SLN raises the possibility of tumour
spread to the rest of the axillary nodes. Current guidelines
therefore recommend ALND whenever the SLN is involved
by tumour, including by micrometastasis. The rationale for
this is implied fromprevious experience with breastconserv-
ing surgery where it was shown that optimal postoperative
irradiation did not reduce the risk of local recurrence if the
surgical margins were inadequate, implying thatresidual dis-
ease may not be completely eradicated by adjuvant treat-
ment. The Z0011 trial, however, reported results to the con-
trary. This study found no increase in recurrence nor any
survival disadvantage in women with a positive SLN who did
not undergo completion ALND, suggesting that any residual
disease in the non-SLNs nodes may be eﬀectively eradicated
by adjuvant radiation and chemotherapy [6, 7]. It should,
however, be noted that subjects included in the Z0011 study
were a highly selected group, having only limited nodal
disease, postoperative chemotherapy and chest wall irradia-
tion which included the level I and II nodal basins. It is,
therefore, too premature to conclude that it is safe to omit
ALND in all patients with a positive SLN.
ALNDistheoreticallyunnecessarywhenthereisnoaddi-
tional involvement of the non-SLN nodes. In our study,
55% of patients with a positive SLN had no involvement of
additionalnon-SLNs,inagreementwithreportsinthelitera-
ture [16]. Although several models have been developed to
predict the likelihood of non-SLN involvement, none have
gained acceptance into routine practice. We have chosen to
validate the MSKCC nomogram and the Tenon score as they
were found to outperform other available models [15]. Both
models are easy to use, the Tenon score being based on the
sum of 3 variables to give a total score of 7, and an online
calculator being available for the MSKCC nomogram. Both
the MSKCC nomogram and Tenon score performed more
poorly in our study population as compared to previous re-
ports in Western populations, with an AUC of 0.69 and 0.71
respectively [8, 9, 17–19]. Although patients with SLN in-
volvement alone had a signiﬁcantly lower Tenon score as
compared to those with additional non-SLN involvement,
the median score of 5.0 was higher than the proposed thresh-
old. Barranger and colleagues proposed a threshold of 3.5
since scores of 3.5 or less were associated with a 97.3%
likelihood of having no additional non-SLN metastases [12].
If this threshold had been applied, only 24 patients in our
study population would have avoided ALND. The median
MSKCC probability among those with SLN involvement
alone was 19.5%. Similarly, if the proposed threshold of
10% was taken, only 15 patients would have avoided ALND
[8]. These ﬁndings suggest that a higher threshold may
be necessary for Asian patients and may explain why both
models performed more poorly in our study population. On
the other hand, only 1 of the 11 patients who underwent
a second surgery for ALND after metastatic deposits were
found on the examination of the permanent sections had ad-
ditional non-SLN involvement. This patient had a Tenon
score of 5.0 and a predicted probability of 18% on the
MSKCC nomogram. Although higher than the respective
proposed thresholds for both models, both scores still fall
within the median scores of those with SLN involvement
alone in our study. Further studies in a larger study popu-
lation will be needed to deﬁne an appropriate threshold for
our population.
In our current practice, the decision ALND is made in-
traoperatively based on results of frozen section analysis of
the SLN. This limits the types of variables that can be used
to predict non-SLN involvement. Currently available mod-
els, including the MSKCC nomogram and Tenon Score, in-
clude variables which require analysis of the permanent for-
malin-ﬁxed paraﬃn-embedded sections and can only be
calculated postoperatively. The ratio of positive SLNs in re-
lation to the total number of SLNs harvested has emerged
as an independent predictor of non-SLN involvement in our
study. This ratio was also found to be signiﬁcant in both the
MSKCC and Tenon models. In our study, 57% of patients
with a positive SLN to total SLN ratio of 1 were found to
have additional non-SLN metastases, as compared to 28%
of those with a ratio of less than 0.5. The reliability of this
ratio depends largely on the accuracy of SLN identiﬁcation
and intraoperative frozen section analysis. In our practice,
the majority of SLN biopsy is performed with blue dye alone.
Our results (SLN nonidentiﬁcation rate of 2.6% and a false
negative rate of 4.5%) are comparable to accepted standards
(unpublished manuscript) [2, 4]. A possible criticism is that
fewer SLNs are identiﬁed using blue dye alone. However, the
median number of SLNs harvested per patient in our study
was similar to that harvested in the study population from
which the Tenon score was derived, where both blue dye and6 ISRN Oncology
r a d i o c o l l o i dw e r eu s e di nc o m b i n a t i o n[ 12]. Although we
found the total number of SLNs harvested to be inversely
correlated with the likelihood of non-SLN involvement, we
failed to deﬁne an optimal number of SLNs that should be
harvested. The median number of SLNs harvested in our pa-
tients was 2, occurring in 68 patients (62%). Although non-
SLN involvement appeared more likely in patients when less
than 2 SLNs were harvested, this did not reach statistical
signiﬁcance. Some studies have suggested that 3 is the opti-
mal number of SLNs that should be harvested; fewer SLNs
carry the risk of understaging, while the examination of
more than 3 nodes does not increase sensitivity [20, 21]. Our
sample size is likely too small for a signiﬁcant correlation
with the total number of SLNs harvested to be observed. We
routinely perform intraoperative frozen section SLN anal-
ysis, with a false negative rate of 16%, often resulting from
micrometastasis being found in deeper layers of the perma-
nent sections (unpublished manuscript).
Thegroupof15patientswithmicrometastasisintheSLN
is of particular interest. Current guidelines recommend
ALNDwhentheSLNisinvolvedbymicrometastasissincethe
possibility of non-SLN involvement cannot be ignored [22].
On the other hand, we have observed that micrometastasis
alone predict for a low likelihood of additional non-SLN
involvement;only1ofthe15patientswasfoundtohavenon-
SLN involvement. Several authors have proposed that a sub-
groupofpatientswithmicrometastasishavesuchanegligible
risk of non-SLN involvement that completion ALND may
not be necessary; this group includes patients with tumour
size of less than 10mm, or less than 20mm if of tubular,
colloid, or medullary histology and micrometastatic deposits
less than 1mm in size [3, 22–25]. Of note is that more than
70% (11 of 15) of the patients with micrometastasis in our
study had a Tenon score of 3.5 or less, suggesting that they
might have avoided ALND if the threshold of 3.5 had been
applied. Only 3 patients had a predicted MSKCC probability
of less than 10%. It would seem that the Tenon score per-
forms better, although both models have been reported to
perform equally well in patients with micrometastasis [15,
26]. However, our study population is too small to allow us
to draw any ﬁrm conclusions.
5. Conclusion
Although both the MSKCC nomogram and Tenon score
diﬀerentiated between patients with SLN involvement only
and those with non-SLN involvement, they performed less
wellthanpreviouslyreported. Itispossible thattheproposed
threshold for both models may need to be adjusted for Asian
populations. The number of positive SLNs, the total number
ofSLNsharvested,andthesizeofthetumourdepositswithin
the SLN were found to be independent predictors of non-
SLN involvement. These variables are particularly relevant to
ourcurrentpracticewherethedecisionforALNDisbasedon
intraoperative frozensectionSLNanalysis.Furtherstudies to
evaluatethepredictivepotentialofthesefactorswillnodoubt
be useful in reducing the rate of unnecessary ALND in those
with a negligible likelihood of non-SLN involvement.
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